HCPCS Code J2680: Fluphenazine decanoate billing guide

Key takeaways

HCPCS Code J2680 covers injection, fluphenazine decanoate, up to 25 mg. It is a long-acting antipsychotic used for schizophrenia and related psychotic disorders.

Medicare pays J2680 at ASP plus 6% in the physician office. Check the current amount in the CMS Medicare Part B drug ASP pricing files, which are updated quarterly.

An NDC must be reported alongside J2680 on every Medicare and Medicaid claim, and CPT 96372 bills separately for the administration.

Pabau’s claims management tools submit and track J2680 claims, and flag common claim errors before they reach the payer.

HCPCS Code J2680 is a Level II code that covers the drug cost of a fluphenazine decanoate injection, up to 25 mg. It pays for the medication alone. The injection itself bills separately under CPT 96372, on the same claim. This guide covers the descriptor, Medicare’s ASP payment basis, NDC reporting, and the CPT pairing. It also covers ICD-10 crosswalks and the errors that most often send a J2680 claim back.

What is HCPCS Code J2680?

HCPCS Code J2680 is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS). It describes the injection of fluphenazine decanoate, up to 25 mg, given by a clinician in an office or outpatient setting. The code sits in the category “Drugs Administered Other than Oral Method”. That is the standard classification for physician-administered injectable medications billed to Medicare Part B and Medicaid.

Unlike a CPT procedure code, HCPCS Code J2680 represents only the drug component of the service. The administration itself requires a separate CPT billing line. Payers use J-codes to calculate drug reimbursement independently from the injection procedure fee. Both codes must appear on the same claim for payment to process correctly.

Drug description: fluphenazine decanoate

Prolixin Decanoate is the brand name for fluphenazine decanoate, a first-generation antipsychotic in the phenothiazine class. Clinicians prescribe it for schizophrenia and other chronic psychotic disorders where medication adherence is a clinical concern. As a long-acting injectable, the depot formulation releases medication over two to four weeks. That removes the daily oral dose from the treatment plan, which matters most in high-relapse populations.

The HCPCS descriptor covers dosages “up to 25 mg” per injection event. Clinicians may give doses below 25 mg based on patient response and prescribing guidelines. J2680 covers the billing unit regardless of the exact dose, as long as it does not exceed 25 mg. Do not read clinical dosing guidance out of a HCPCS descriptor. The FDA prescribing information is the source for dosing protocols.

• Drug class: First-generation antipsychotic (phenothiazine)
• Brand name: Prolixin Decanoate
• Administration route: Intramuscular (IM) injection, deep gluteal
• Dosing interval: Typically every 2-4 weeks, per prescribing information
• Primary indication: Schizophrenia and chronic psychotic disorders requiring adherence support
• Billing unit: Up to 25 mg per J2680 claim line

How Medicare pays for J2680

Medicare Part B pays J2680 under the Average Sales Price methodology, at ASP plus 6% in physician office settings. CMS calculates ASP from manufacturer-reported sales data and updates it quarterly. No dollar figure printed in an article stays current for long. Check the active amount in the CMS Medicare Part B drug ASP pricing files before you bill.

Payment also varies by Medicare Administrative Contractor (MAC) jurisdiction. Facility rates for hospital outpatient and non-facility rates for the physician office differ, and office-based psychiatry practices bill the non-facility rate. Confirm your practice’s MAC jurisdiction before you set internal fee schedules, because the same J2680 line can pay differently by location.

NDC codes associated with J2680

CMS requires providers to report National Drug Codes (NDCs) on all Medicare Part B claims for physician-administered drugs billed with HCPCS J-codes. J2680 maps to several NDCs, depending on the manufacturer, labeler, and package size of the product actually given. An outdated or mismatched NDC is one of the most common rejection triggers on this code.

NDC codes follow an 11-digit format (5-4-2) and belong in box 24 of the CMS-1500, with the N4 qualifier on electronic claims. Verify current NDCs through the NLM HCPCS code search tool or FDA’s DailyMed. Manufacturers reformulate products and discontinue package sizes, which makes previously valid NDCs inactive. A static NDC list published in any article, this one included, may not match your shelf. Use your pharmacy supplier’s current product documentation as the primary source.

How to bill J2680: the buy-and-bill process

J2680 follows the buy-and-bill model. The practice purchases fluphenazine decanoate, gives it in the office, and bills both the drug and the administration to the payer. The two codes travel on one claim, but they reimburse through separate payment mechanisms.

1. Purchase the drug: Order fluphenazine decanoate from an authorized pharmaceutical supplier. Document the NDC, lot number, and acquisition cost.
2. Verify coverage before administration: Confirm the patient’s benefit coverage for J2680, and check whether prior authorization is required, before the appointment.
3. Administer the injection: Document the drug name, dose given (up to 25 mg), route, site, clinician credentials, and date in the patient record.
4. Build the claim: Report J2680 for the drug component. Report the 11-digit NDC with the N4 qualifier in box 24 on the CMS-1500. Add CPT 96372 on a separate line for the administration service.
5. Submit to payer: Submit to Medicare, Medicaid, or the commercial payer, and attach prior authorization documentation where the payer requires it.

Both lines leave the practice on one claim, and each is paid on its own basis. The diagram below shows what each line carries, and the three requirements that sink both lines when they are missing.

Paired CPT administration code: CPT 96372

HCPCS Code J2680 covers the drug cost only. The act of injecting fluphenazine decanoate bills separately, on the same claim. CPT 96372 covers a therapeutic, prophylactic, or diagnostic injection given subcutaneously or intramuscularly, and it is the standard pairing for J2680. The full administration rules, including how the code applies to other injection routes, sit on the page for CPT 96372.

One billing distinction decides most 96372 edits. The code is not separately billable when a visit bundles the injection into a service with no distinct, separately identifiable E/M component. Documenting and billing that service with modifier 25 lets both lines stand. When the patient presents solely for the injection, 96372 is billable on its own. Record which of those happened, so the claim survives the edit.

ICD-10 diagnosis codes billed with J2680

Every J2680 claim must link to a diagnosis code that establishes medical necessity. Fluphenazine decanoate is indicated for schizophrenia and related psychotic disorders, so the codes below are the most commonly paired diagnoses. They belong in the diagnosis fields of the CMS-1500 and must match the clinical documentation. Reporting a diagnosis the record does not support is a compliance risk, even where the drug itself is clinically appropriate.

These pairings reflect commonly billed associations for fluphenazine decanoate, not coverage guarantees. Medical necessity comes from the clinical documentation, not from the diagnosis code by itself. Check for an applicable Local Coverage Determination (LCD) from your MAC contractor, and confirm payer-specific crosswalks at the plan level.

Prior authorization requirements for J2680

Medicare generally does not require prior authorization for J2680 in physician office settings. Commercial payers frequently do require it for long-acting antipsychotic injectables, fluphenazine decanoate included. Whether PA applies at all, and which clinical criteria attach to it, varies by payer and plan year.

• Medicare: PA is typically not required; verify with your MAC for plan-specific exceptions.
• Medicaid: Requirements vary significantly by state. Some state programs run preferred drug lists that require step therapy before they approve an LAI.
• Commercial payers: PA is frequently required. Common criteria include a documented schizophrenia or schizoaffective diagnosis, evidence of prior medication trials, and psychiatric provider attestation.
• Best practice: Verify coverage and PA requirements before the injection. A retroactive denial on a drug already given leaves the practice holding the acquisition cost.

Build the PA check into the pre-visit workflow as its own step. Practices that fold PA status into the eligibility check tend to confirm the first and assume the second. Confirming authorization before staff order the drug is what keeps the acquisition cost off the practice’s books.

Modifiers that apply to J2680

Modifiers on J2680 tell the payer about the route of administration or the clinical circumstances of the injection. The wrong modifier, or a missing required one, is a fast path to a claim edit. The table below covers the modifiers most often raised on fluphenazine decanoate claims.

For standard office-based IM administration, most J2680 claims need no route-of-administration modifier beyond what CPT 96372 already specifies. Confirm modifier requirements with your MAC contractor or the commercial payer’s billing guidelines before submitting, particularly where plan-specific policies apply.

Payer coverage and medical necessity criteria

Medicare covers J2680 under Part B when a physician administers the drug in an eligible setting and documents medical necessity. Applicable Local Coverage Determinations and National Coverage Determinations govern coverage, and neither guarantees payment without supporting documentation. Medicaid coverage varies by state and may involve preferred drug lists, step therapy, or quantity limits.

Commercial criteria typically require a qualifying diagnosis, failure of or contraindication to oral antipsychotics, and psychiatric provider attestation of medical necessity. Maintain a clinical record that supports the LAI selection, because it is the first document an auditor asks for.

Common billing errors and how to avoid them

J2680 generates a predictable set of claim errors. Most denials on fluphenazine decanoate claims fall into six categories, and each one is preventable with the right pre-submission check. Reading the medical billing denial codes your payers actually return is the fastest way to see which of the six is costing you.

• Missing or incorrect NDC: The most common rejection. The NDC must be in 11-digit 5-4-2 format with the N4 qualifier, and it must match the product label at the time of administration.
• Wrong unit count: J2680 covers up to 25 mg per unit. Where a dose spans multiple vials, confirm with your MAC whether you bill units as drug units or dosing units.
• Missing CPT 96372: Submitting J2680 without the paired administration code leaves the drug claim orphaned. Both belong on the same claim for complete reimbursement.
• Incorrect or missing modifier: Applying JA to an IM injection is a route mismatch that triggers an edit. Confirm the route before selecting a modifier.
• Missing diagnosis code: A J2680 claim without a supporting ICD-10 code will not process. F20.9 or the appropriate psychotic disorder code must appear in the diagnosis field.
• No prior authorization documentation: On commercial claims, omitting the PA authorization number where one is required results in immediate denial. Build PA confirmation into the pre-visit checklist.

Tracking these denial patterns in your practice management system turns each rejection into a process fix rather than a one-off correction. Use the AAPC HCPCS code lookup to cross-reference J2680 billing rules and modifier requirements when a new payer returns an unfamiliar edit.

How Pabau supports J2680 claims and prior authorization tracking

Psychiatry and behavioral health practices running long-acting injectables carry a steady schedule of repeat appointments. Each visit produces a two-line claim, an NDC to record, and a PA status to confirm. Handling that work by hand puts it on the same person every week.

Practice management software like Pabau keeps the billing record next to the appointment and the clinical note. Claims management software submits the claim and tracks it through to payment. Your team can see where a J2680 line sits without logging into a payer portal.

Claim scrubbing flags common errors before submission, while the claim is still editable. Pabau records denial reasons against the claim, giving the practice a pattern to work from instead of a stack of separate rejections.

Submit and track J2680 claims in one place

Pabau’s claims management tools help behavioral health and psychiatry practices submit J2680 claims, track them through to payment, and flag common errors before submission. Your billing team spends less time reworking rejections.

Book a demo

Conclusion

J2680 rewards process over memory. The descriptor rarely changes, but the NDC on the vial, the payer’s PA rules, and the quarterly ASP amount all move independently of it. A claim built from what the biller remembers will eventually be built from something that has since changed.

So put the checks in the appointment rather than the appeal. Confirm coverage before you order the drug, read the NDC off the label at administration, and keep both claim lines together. A practice that does this consistently spends its billing time on new claims rather than old ones.

Book a demo to see how Pabau handles J2680 claim submission, tracking, and denial follow-up for behavioral health practices.

Continue your research

Need the administration code that pairs with J2680? CPT code 96372 sets out how the injection service is reported alongside the drug line.

Looking to reduce denied claims across your behavioral health practice? Denial management in healthcare explains how to track root causes and build systematic fixes for recurring payer rejections.

Want to verify insurance coverage before every injection appointment? Insurance eligibility verification outlines the pre-visit workflow for confirming coverage, PA status, and plan-specific requirements.

Want fewer J-code claims coming back? Clean claim submission covers the checks that get a claim paid the first time it reaches the payer.

Frequently asked questions